NASDAQ:YMAB

Y-mAbs Therapeutics Stock Forecast, Price & News

$35.32

+0.15 (+0.43 %)

(As of 03/1/2021 11:07 AM ET)

Add

Compare

Today's Range

$35.00

Now: $35.32▼

$37.05

50-Day Range

$33.68

MA: $45.48▼

$51.96

52-Week Range

$14.16

Now: $35.32▼

$55.22

Volume5,166 shs

Average Volume265,839 shs

Market Capitalization$1.43 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.36

Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. The company develops naxitamab that is in Phase 2 clinical trial for the treatment of pediatric patients with relapsed steosarcoma or refractory, and high-risk neuroblastoma, as well as other GD2 positive tumors; and GD2-GD3 Vaccine which is in Phase 2 clinical trial for the treatment of high-risk neuroblastoma. It is developing omburtamab that is in Phase 2 clinical trial for the treatment of desmoplastic small round cell tumors; in Phase 1 clinical trial for the treatment of diffuse intrinsic pontine glioma, as well as for the treatment of pediatric patients with central nervous system and leptomeningeal metastases; The company also engages in the development of huB7-H3 product candidate for the treatment of B7-H3 positive adult solid tumors; and pre clinical development of huCD33 BsAb product candidate for the treatment of huCD33 positive hermatological cancers. The company has a license and research collaboration agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize antibody constructs based on the SADA-BiDE pre-targeted radioimmunotherapy platform. Y-mAbs Therapeutics, Inc. was founded in 2015 and is headquartered in New York, New York.

Headlines

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Analysts Are Reducing Their Forecasts For This Year
March 1, 2021 | finance.yahoo.com

Could The Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Ownership Structure Tell Us Something Useful?
February 25, 2021 | finance.yahoo.com

Y-mAbs Announces 2020 Financial Results and Recent Corporate Developments
February 25, 2021 | finance.yahoo.com

Y-mAbs to Announce 2020 Financial and Operating Results on February 25, 2021
February 19, 2021 | finance.yahoo.com

Y-mAbs Therapeutics (YMAB) Shares Cross Below 200 DMA
February 17, 2021 | nasdaq.com

United Therapeutics launches first product of 2021 after Covid-related delays
February 10, 2021 | bizjournals.com

YMAB Feb 2021 70.000 call
January 17, 2021 | au.finance.yahoo.com

Y-mAbs Therapeutics to Present At 39th Annual J.P. Morgan Healthcare Conference
January 6, 2021 | finance.yahoo.com

Y-mAbs Announces Sale of Priority Review Voucher
December 28, 2020 | finance.yahoo.com

Y-mAbs Therapeutics: Further Upside After Approval
December 21, 2020 | seekingalpha.com

Week In Review: Week's China Life Science Investments Total $800 Million
December 20, 2020 | seekingalpha.com

Y-mAbs Signs Distribution Agreement with Swixx for DANYELZA(R) (naxitamab-gqgk) and Omburtamab in Eastern Europe
December 18, 2020 | marketwatch.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:YMAB

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.ymabs.com

Phone646-885-8505

Employees65

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current Ratio10.40

Quick Ratio10.40

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$5.01 per share

Price / Book7.05

Profitability

EPS (Most Recent Fiscal Year)($2.30)

Net Income$-81,030,000.00

Net MarginsN/A

Return on Equity-74.98%

Return on Assets-66.70%

Miscellaneous

Outstanding Shares40,514,000

Market Cap$1.43 billion

Next Earnings DateN/A

OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.61 out of 5 stars

Medical Sector

325th out of 1,962 stocks

Pharmaceutical Preparations Industry

157th out of 772 stocks

3.4 Analyst's Opinion

Consensus Rating
Y-mAbs Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $59.17, Y-mAbs Therapeutics has a forecasted upside of 67.5% from its current price of $35.32.
Amount of Analyst Coverage
Y-mAbs Therapeutics has only been the subject of 4 research reports in the past 90 days.

2.4 Community Rank

Outperform Votes
Y-mAbs Therapeutics has received 89 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Y-mAbs Therapeutics has received 95 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Y-mAbs Therapeutics has received 51.63% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Y-mAbs Therapeutics and other stocks. Vote “Outperform” if you believe YMAB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe YMAB will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Y-mAbs Therapeutics does not currently pay a dividend.
Dividend Growth
Y-mAbs Therapeutics does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Y-mAbs Therapeutics insiders have sold 54,922.98% more of their company's stock than they have bought. Specifically, they have bought $11,890.00 in company stock and sold $6,542,232.00 in company stock.
Percentage Held by Insiders
38.40% of the stock of Y-mAbs Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
53.20% of the stock of Y-mAbs Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Y-mAbs Therapeutics are expected to grow in the coming year, from ($3.25) to ($1.01) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Y-mAbs Therapeutics is -11.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Y-mAbs Therapeutics is -11.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Y-mAbs Therapeutics has a P/B Ratio of 7.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

$35.32

+0.15 (+0.43 %)

(As of 03/1/2021 11:07 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive YMAB News and Ratings via Email

Sign-up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter.

Y-mAbs Therapeutics (NASDAQ:YMAB) Frequently Asked Questions

Is Y-mAbs Therapeutics a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Y-mAbs Therapeutics in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Y-mAbs Therapeutics stock.
View analyst ratings for Y-mAbs Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Y-mAbs Therapeutics?

Wall Street analysts have given Y-mAbs Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Y-mAbs Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Y-mAbs Therapeutics?

Y-mAbs Therapeutics saw a decline in short interest in February. As of February 12th, there was short interest totaling 2,230,000 shares, a decline of 24.1% from the January 28th total of 2,940,000 shares. Based on an average trading volume of 251,700 shares, the days-to-cover ratio is presently 8.9 days. Approximately 8.3% of the company's stock are sold short.
View Y-mAbs Therapeutics' Short Interest.

How were Y-mAbs Therapeutics' earnings last quarter?

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) released its earnings results on Friday, February, 26th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.36.
View Y-mAbs Therapeutics' earnings history.

How has Y-mAbs Therapeutics' stock been impacted by Coronavirus?

Y-mAbs Therapeutics' stock was trading at $22.98 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, YMAB stock has increased by 56.4% and is now trading at $35.95.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for YMAB?

8 brokerages have issued 1 year target prices for Y-mAbs Therapeutics' shares. Their forecasts range from $45.00 to $71.00. On average, they anticipate Y-mAbs Therapeutics' stock price to reach $59.17 in the next year. This suggests a possible upside of 64.6% from the stock's current price.
View analysts' price targets for Y-mAbs Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Y-mAbs Therapeutics' key executives?

Y-mAbs Therapeutics' management team includes the following people:

Mr. Thomas Gad, Founder, Chairman, Pres & Head of Bus. Devel. and Strategy (Age 51, Pay $766.75k)
Dr. Claus Juan MÃ¸ller San Pedro M.D., Ph.D., CEO & Director (Age 59, Pay $967.5k)
Mr. Bo Kruse, Exec. VP, Sec., Treasurer & CFO (Age 49, Pay $608.35k)
Mr. Joris Wiel Jan Wilms, Sr. VP & COO (Age 47)
Dr. Torben Lund-Hansen, Sr. VP & Head of Technical Operations (Age 70)
Dr. Steen Lisby M.D., M.Sc., Sr. VP & Chief Scientific Officer (Age 57)
Mr. Philip Herman, Sr. VP & Chief Commercial Officer (Age 42)
Dr. Vignesh Rajah, Sr. VP & Chief Medical Officer

Who are some of Y-mAbs Therapeutics' key competitors?

Some companies that are related to Y-mAbs Therapeutics include Blueprint Medicines (BPMC), Turning Point Therapeutics (TPTX), Perrigo (PRGO), Maravai LifeSciences (MRVI), Galapagos (GLPG), Emergent BioSolutions (EBS), Biohaven Pharmaceutical (BHVN), Arena Pharmaceuticals (ARNA), Eidos Therapeutics (EIDX), ChemoCentryx (CCXI), FibroGen (FGEN), Sage Therapeutics (SAGE), I-Mab (IMAB), Hutchison China MediTech (HCM) and Reata Pharmaceuticals (RETA).
View all of YMAB's competitors.

What other stocks do shareholders of Y-mAbs Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Y-mAbs Therapeutics investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Corbus Pharmaceuticals (CRBP), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV), Occidental Petroleum (OXY), VBI Vaccines (VBIV), Vaxart (VXRT) and Amarin (AMRN).

When did Y-mAbs Therapeutics IPO?

(YMAB) raised $80 million in an initial public offering (IPO) on Friday, September 21st 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity served as the underwriters for the IPO and BTIG was co-manager.

What is Y-mAbs Therapeutics' stock symbol?

Y-mAbs Therapeutics trades on the NASDAQ under the ticker symbol "YMAB."

Who are Y-mAbs Therapeutics' major shareholders?

Y-mAbs Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (5.97%), Artisan Partners Limited Partnership (2.59%), Alliancebernstein L.P. (2.49%), Northern Trust Corp (0.87%), Ashford Capital Management Inc. (0.54%) and New York State Common Retirement Fund (0.49%). Company insiders that own Y-mAbs Therapeutics stock include Bo Kruse, David N Gill, James Healy, Johan Wedell-Wedellsborg, Mahiuddin Ahmed, Pedro Claus Juan Moller-San, Thomas Gad and Vignesh Rajah.
View institutional ownership trends for Y-mAbs Therapeutics.

Which major investors are selling Y-mAbs Therapeutics stock?

YMAB stock was sold by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Barclays PLC, Aviva PLC, Northern Trust Corp, SG Americas Securities LLC, State of Wisconsin Investment Board, Candriam Luxembourg S.C.A., and Credit Suisse AG. Company insiders that have sold Y-mAbs Therapeutics company stock in the last year include Bo Kruse, David N Gill, Mahiuddin Ahmed, Pedro Claus Juan Moller-San, and Thomas Gad.
View insider buying and selling activity for Y-mAbs Therapeutics or view top insider-selling stocks.

Which major investors are buying Y-mAbs Therapeutics stock?

YMAB stock was bought by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Ashford Capital Management Inc., BlackRock Inc., Morgan Stanley, Alliancebernstein L.P., New York State Common Retirement Fund, Brookfield Asset Management Inc., and DNB Asset Management AS. Company insiders that have bought Y-mAbs Therapeutics stock in the last two years include James Healy, Pedro Claus Juan Moller-San, and Vignesh Rajah.
View insider buying and selling activity for Y-mAbs Therapeutics or or view top insider-buying stocks.

How do I buy shares of Y-mAbs Therapeutics?

Shares of YMAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Y-mAbs Therapeutics' stock price today?

One share of YMAB stock can currently be purchased for approximately $35.95.

How much money does Y-mAbs Therapeutics make?

Y-mAbs Therapeutics has a market capitalization of $1.46 billion. The company earns $-81,030,000.00 in net income (profit) each year or ($2.30) on an earnings per share basis.

How many employees does Y-mAbs Therapeutics have?

Y-mAbs Therapeutics employs 65 workers across the globe.

What is Y-mAbs Therapeutics' official website?

The official website for Y-mAbs Therapeutics is www.ymabs.com.

Where are Y-mAbs Therapeutics' headquarters?

Y-mAbs Therapeutics is headquartered at 230 Park Avenue Suite 3350, NEW YORK NY, 10169.

How can I contact Y-mAbs Therapeutics?

Y-mAbs Therapeutics' mailing address is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. The company can be reached via phone at 646-885-8505 or via email at [email protected]

This page was last updated on 3/1/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here